Cited by 327Opioid Use Disorder TreatmentPrenatal Substance Exposure EffectsSubstance Abuse Treatment and Outcomes

Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts

Open access
Schiff, Davida M., Nielsen, Timothy, Terplan, Mishka, Hood, Malena, Bernson, Dana, Diop, Hafsatou, Bharel, Monica, Wilens, Timothy E. +3 more·2018·Obstetrics & Gynecology

Abstract

OBJECTIVE: To estimate fatal and nonfatal opioid overdose events in pregnant and postpartum women in Massachusetts, comparing rates in individuals receiving and not receiving pharmacotherapy for opioid use disorder (OUD). METHODS: We conducted a population-based retrospective cohort study using linked administrative and vital statistics databases in Massachusetts to identify women with evidence of OUD who delivered a liveborn neonate in 2012–2014. We described maternal sociodemographic, medical, and substance use characteristics, computed rates of opioid overdose events in the year before and after delivery, and compared overdose rates by receipt of pharmacotherapy with methadone or buprenorphine in the prenatal and postpartum periods. RESULTS: Among 177,876 unique deliveries, 4,154 (2.3%) were to women with evidence of OUD in the year before delivery, who experienced 242 total opioid-related overdose events (231 nonfatal, 11 fatal) in the year before or after delivery. The overall overdose rate was 8.0 per 100,000 person-days. Overdoses were lowest in the third trimester (3.3/100,000 person-days in the third trimester) and then increased in the postpartum period with the highest overdose rate 7–12 months after delivery (12.3/100,000 person-days). Overall, 64.3% of women with evidence of OUD in the year before delivery received any pharmacotherapy in the year before delivery. Women receiving pharmacotherapy had reduced overdose rates in the early postpartum period. CONCLUSION: Pregnant women in Massachusetts have high rates of OUD. The year after delivery is a vulnerable period for women with OUD. Additional longitudinal supports and interventions tailored to women in the first year postpartum are needed to prevent and reduce overdose events.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/aog.0000000000002734

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [7]Hogan L Rutherford BK Schrader DR MARYLAND MATERNAL MORTALITY REVIEW 2016 ANNUAL REPORT Health – General Article 13-1203—1207
  2. [8]Kavanaugh V Pregnancy-Associated Deaths From Drug Overdose in Virginia, 1999–2007: A Report from the Virginia Maternal Mortality Review Team 2015

Cited by

Sorted by citations

Authors
Schiff, D. M., Nielsen, T., Terplan, M., Hood, M., Bernson, D., Diop, H., Bharel, M., Wilens, T. E., LaRochelle, M., Walley, A. Y., & Land, T.
Affiliations
Boston Medical Center (US)
Venue
Obstetrics & Gynecology
Published
2018-08
Volume
132
Issue
2
Pages
466-474
ISSN
0029-7844 (ISSN-L)
OpenAlex
W2876455145
Cited by
327
References
24
Citations by year
2026: 33 · 2025: 39 · 2024: 38 · 2023: 59 · 2022: 36 · 2021: 55 · 2020: 39 · 2019: 26 · 2018: 2
FWCI
29.03
Type
journal article
Language
en
Open access
Locations
  • Obstetrics and Gynecology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute on Drug Abuse (K23DA042168)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Substance Exposure Effects
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
opioid overdose, opioid use disorder, pregnancy, postpartum period, maternal health, methadone, buprenorphine, opioid therapy, overdose prevention
MeSH terms
Adult, Buprenorphine, Female, Humans, Massachusetts, Methadone, Opioid-Related Disorders, Pregnancy, Pregnancy Complications, Puerperal Disorders, Retrospective Studies, Opiate Substitution Treatment, Drug Overdose

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review